Mylan launches Hep C generic drug in India - Feedback

Mylan Pharmaceuticals, an arm of Mylan N.V., has on Thursday launched its generic drug Harvoni under the brandname MyHep LVIRTM in the Indian market. The drug is a combination of Ledipasvir/Sofosbuvir and is indicated for the treatment of Hepatitis C infection.

It offers a simplified Hepatitis C treatment regimen that eliminates the need for interferon and ribavirin. The product also is a single-tablet regimen and requires a therapy course of 12 weeks.

About news

We take care of publishing the latest investment news and highlights for Feedback

Leave a Reply

Your email address will not be published. Required fields are marked *